Erythropoietic Protoporphyria (EPP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Erythropoietic protoporphyria is a genetic condition that affects heme production, which leads to the overproduction of protoporphyrin, majorly in the bone marrow. This condition leads to higher levels of the heme precursor excreted in the bile. In some cases, this disorder progresses to liver disease and eventually ends with liver transplantation. Since the bone marrow continues to produce excessive protoporphyrin after the transplant, the condition can recur in the transplanted liver. As a result, liver transplantation, while a potential treatment, tends to be a palliative measure rather than a cure due to the risk of recurrence. EPP can result from mutations of the ferrochelatase gene (FECH). Children develop pain, redness, swelling, pruritus, and a variety of hepatobiliary complications. The 5%–10% of subjects have an X-linked variant of EPP (termed XLPP) resulting from a gain-of-function mutation of the Alas2 gene.41 Mild microcytic anemia occurs in 20%–60% of patients with some evidence of iron deficiency.

Thelansis’s “Erythropoietic Protoporphyria (EPP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Erythropoietic Protoporphyria (EPP) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Erythropoietic Protoporphyria (EPP) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Erythropoietic Protoporphyria (EPP) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Erythropoietic Protoporphyria (EPP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033